Valsartan

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Jul 1, 2006 → —

NCT ID

NCT00415883

About Valsartan

Valsartan is a phase 1 stage product being developed by Novartis for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT00415883. Target conditions include Healthy.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01541189	Approved	Completed	Feb 1, 2012	Jan 1, 2013	Hypertension
NCT00627991	Pre-clinical	Withdrawn	Aug 1, 2007	—	Cerebrovascular Accident
NCT00550095	Approved	Completed	Jun 1, 2007	Nov 1, 2009	Microalbuminuria
NCT00457626	Phase 3	Completed	Apr 9, 2007	May 25, 2009	Hypertension
NCT01425411	Approved	Completed	Nov 1, 2006	Nov 1, 2008	Hypertension
NCT00589732	Approved	Completed	Sep 1, 2006	Dec 1, 2009	Coronary Artery Disease
NCT00415883	Phase 1	Completed	Jul 1, 2006	—	Healthy
NCT00394745	Phase 3	Completed	Nov 1, 2005	Jun 1, 2007	Hypertension
NCT00343499	Approved	Terminated	Nov 1, 2004	Jul 1, 2007	Atrial Fibrillation
NCT00170924	Approved	Completed	Aug 1, 2004	Jun 1, 2006	Diastolic Dysfunction
NCT00171353	Approved	Completed	Jul 1, 2004	Sep 1, 2005	Hypertension
NCT00333489	Approved	Completed	Mar 1, 2004	Apr 1, 2005	Hypertension
NCT00171119	Approved	Terminated	Jan 1, 2004	—	Hypertension
NCT00171028	Phase 3	Completed	Dec 1, 2003	Nov 1, 2006	Hypertension
NCT00241137	Phase 3	Completed	Sep 1, 2003	Jan 1, 2005	Hypertension
NCT00241098	Approved	Completed	May 1, 2003	Jun 1, 2005	Hypertension
NCT00171041	Phase 3	Completed	Dec 1, 2002	Mar 1, 2006	Hypertension
NCT00171106	Approved	Completed	Dec 1, 2002	Feb 1, 2008	Diastolic Dysfunction, Symptomatic Heart Failure
NCT00241150	Approved	Completed	Nov 1, 2002	Jan 1, 2005	Hypertension
NCT00241085	Approved	Completed	Nov 1, 2002	Aug 1, 2005	PROTEINURIA

Competing Products

20 competing products in Healthy

See all competitors

Product	Company	Stage	Hype Score
AZD0837	AstraZeneca	Phase 1	33
CSL112 + Placebo	CSL	Phase 1	32
UT-15C	United Therapeutics	Phase 1	30
VNA-318 + Placebo	Biotrial	Phase 1	25
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + Placebo	Trevena	Phase 1	25
TRV130 + Moxifloxacin + Placebo	Trevena	Phase 1	25
Radiolabeled TRV130	Trevena	Phase 1	25
TRV130A + Dextrose in Water	Trevena	Phase 1	25
TRV734	Trevena	Phase 1	25
ALT02 + EU-licensed Herceptin + US-licensed Herceptin	Alteogen	Phase 1	33
ENZ215 + EU Sourced Prolia + US Sourced Prolia	Alkem Laboratories	Phase 1	33
KPL-404	Kiniksa Pharmaceuticals	Phase 1	28
MORF-057 + Placebo for MORF-057	Eli Lilly	Phase 1	33
Propranolol + Pseudoephedrine	Eli Lilly	Pre-clinical	23
LY2157299	Eli Lilly	Phase 1	33
Lasmiditan + Placebo	Eli Lilly	Phase 1	33
LY3015014 + Placebo	Eli Lilly	Phase 1	33
LOXO-783	Eli Lilly	Phase 1	33
LY2541546 - IV + LY2541546 - SC + Placebo	Eli Lilly	Phase 1	33
LY3867070 + Placebo	Eli Lilly	Phase 1	33

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved